Pfizer’s Vydura recommended by NICE for acute migraines
The treatment is the first oral GPCR receptor antagonist class recommended for NHS use
Read More
Tag: rimegepant
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
